Piramal Pharma Solutions, a leading global contract development and manufacturing organisation (CDMO) and part of Piramal Pharma Ltd, is proud to announce the completion of the 1500th antibody-drug conjugate (ADC) batch at its dedicated bioconjugate development and manufacturing facility in Grangemouth, UK.
With the 1500th batch representing a commercial oncology ADC batch, this milestone highlights the company’s cutting-edge capabilities and unwavering commitment to patient centricity.
For more than two decades, Piramal Pharma Solutions has been a global leader in ADC development and manufacturing.
As the first FDA-approved ADC CDMO and the first CDMO to commercially manufacture an ADC, Piramal demonstrates unmatched proficiency in this segment.
Piramal leverages this expertise to provide a comprehensive range of integrated ADC solutions from Grangemouth, spanning from proof-of-concept studies to clinical- and commercial-scale manufacturing.
These capabilities make the site an essential part of the ADCelerate programme, Piramal’s rapid, integrated Phase I ADC programme.
With seamless tech transfers supported by strong programme management, technical and quality teams, the programme combines the specialised capabilities at Grangemouth with those across Piramal’s global network to streamline the path from R&D to GMP production.
Building on Piramal’s history of ADC leadership, Grangemouth has developed hundreds of unique bioconjugates and has now successfully manufactured 1500 ADC batches, including clinical, commercial and non-GMP batches.
But the facility isn’t just backed by legacy; it’s also supported by the Science Collective’s subject matter experts, who provide technical insight and strategic direction to guide projects to success.
In alignment with Piramal’s commitment to quality, Grangemouth maintains a strong regulatory record, including accreditations from the US FDA and MHRA.
With its unparalleled expertise and advanced solutions, the facility enables Piramal to deliver lifesaving bioconjugate therapies to patients in need with speed, precision and quality.
